Global Bacterial Vaginosis Drug

Bacterial Vaginosis Drug Comprehensive Study by Type (Rx, OTC), Application (Hospital, Pharmacy, Others), End Users (Hospital, Pharmacy, Other) Players and Region - Global Market Outlook to 2027

Bacterial Vaginosis Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Bacterial Vaginosis Drug
Bacterial vaginosis is the infection which is caused due to change in normal balance of bacteria in vagina. It leads to issues when the women is pregnant. Bacterial vaginosis drugs include antibiotics which is present in the form of tablets. In addition, the medication are available in the form of cream or gel. The treatment of bacterial vaginosis include probiotic and medication.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The BV drug market is highly fragmented due to the presence of numerous International and Regional players who are involved in producing Generic Drugs. Small companies are competing strongly with large established vendors. The growth of the vendors in the BV infection treatment market is influenced by factors such as the High prevalence of Infectious Disease and the lack of effective BV treatment. Introduction of new drugs by key companies is expected to propel the market growth Analyst at AMA Research estimates that Europe Players will contribute the maximum growth to Global Bacterial Vaginosis Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Bayer (Germany), Sanofi (France), Piramal (India), Abbott (United States), Galderma (Switzerland), Alkem (India), Teva (Israel), Perrigo (Ireland) and Starpharma (Australia) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Xiuzheng (China).

Segmentation Overview
AMA Research has segmented the market of Global Bacterial Vaginosis Drug market by Type (Rx and OTC), Application (Hospital, Pharmacy and Others) and Region.



On the basis of geography, the market of Bacterial Vaginosis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Hospital will boost the Bacterial Vaginosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Bacterial Vaginosis Drug Market Dynamics:
AttributesDetails
Growth Drivers
  • Rising prevalence of bacterial vaginosis among the women of child bearing age group. The bacterial vaginosis is the most common infection and it may lead to severe infection when untreated. This is contributing towards the growth of bacterial vaginosis drug market.
Influencing Trends
  • Rising awareness about the women’s health
Restraints
  • High Cost of the Bacterial Vaginosis Drug
Road Blocks / Challenges
  • Side Effects of Drugs May Hamper the Market Growth
Gaps & Opportunities
  • Advancements in Healthcare is Boosting the Market Growth
  • Initiatives Taken by Government and Non-Government Organizations


Market Leaders and their expansionary development strategies
In December 2021, Daré Bioscience, Inc. received approval from FDA for its XACIATO, clindamycin phosphate vaginal gel to treat bacterial vaginosis in adult women. The approval will create significant opportunities for the company as well as accelerate the development of differentiated products for women.
In February 2022, Lupin Limited received approval from USFDA for its new drug application, SOLOSEC for bacterial vaginosis treatment. It is the first single-dose oral prescription drug that is used for 12 years of age or older female patients with bacterial vaginosis and trichomoniasis.


Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organizations, Government Agencies and Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Rx
  • OTC
By Application
  • Hospital
  • Pharmacy
  • Others
By End Users
  • Hospital
  • Pharmacy
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of bacterial vaginosis among the women of child bearing age group. The bacterial vaginosis is the most common infection and it may lead to severe infection when untreated. This is contributing towards the growth of bacterial vaginosis drug market.
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Drugs May Hamper the Market Growth
    • 3.4. Market Trends
      • 3.4.1. Rising awareness about the women’s health
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bacterial Vaginosis Drug, by Type, Application, End Users and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Bacterial Vaginosis Drug (Value)
      • 5.2.1. Global Bacterial Vaginosis Drug by: Type (Value)
        • 5.2.1.1. Rx
        • 5.2.1.2. OTC
      • 5.2.2. Global Bacterial Vaginosis Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Pharmacy
        • 5.2.2.3. Others
      • 5.2.3. Global Bacterial Vaginosis Drug by: End Users (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Pharmacy
        • 5.2.3.3. Other
      • 5.2.4. Global Bacterial Vaginosis Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Bacterial Vaginosis Drug (Price)
      • 5.3.1. Global Bacterial Vaginosis Drug by: Type (Price)
  • 6. Bacterial Vaginosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Piramal (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galderma (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alkem (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Perrigo (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Starpharma (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bacterial Vaginosis Drug Sale, by Type, Application, End Users and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Bacterial Vaginosis Drug (Value)
      • 7.2.1. Global Bacterial Vaginosis Drug by: Type (Value)
        • 7.2.1.1. Rx
        • 7.2.1.2. OTC
      • 7.2.2. Global Bacterial Vaginosis Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Pharmacy
        • 7.2.2.3. Others
      • 7.2.3. Global Bacterial Vaginosis Drug by: End Users (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Pharmacy
        • 7.2.3.3. Other
      • 7.2.4. Global Bacterial Vaginosis Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Bacterial Vaginosis Drug (Price)
      • 7.3.1. Global Bacterial Vaginosis Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bacterial Vaginosis Drug: by Type(USD Million)
  • Table 2. Bacterial Vaginosis Drug Rx , by Region USD Million (2016-2021)
  • Table 3. Bacterial Vaginosis Drug OTC , by Region USD Million (2016-2021)
  • Table 4. Bacterial Vaginosis Drug: by Application(USD Million)
  • Table 5. Bacterial Vaginosis Drug Hospital , by Region USD Million (2016-2021)
  • Table 6. Bacterial Vaginosis Drug Pharmacy , by Region USD Million (2016-2021)
  • Table 7. Bacterial Vaginosis Drug Others , by Region USD Million (2016-2021)
  • Table 8. Bacterial Vaginosis Drug: by End Users(USD Million)
  • Table 9. Bacterial Vaginosis Drug Hospital , by Region USD Million (2016-2021)
  • Table 10. Bacterial Vaginosis Drug Pharmacy , by Region USD Million (2016-2021)
  • Table 11. Bacterial Vaginosis Drug Other , by Region USD Million (2016-2021)
  • Table 12. South America Bacterial Vaginosis Drug, by Country USD Million (2016-2021)
  • Table 13. South America Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 14. South America Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 15. South America Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 16. Brazil Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 17. Brazil Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 18. Brazil Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 19. Argentina Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 20. Argentina Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 21. Argentina Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 22. Rest of South America Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 23. Rest of South America Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 24. Rest of South America Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 25. Asia Pacific Bacterial Vaginosis Drug, by Country USD Million (2016-2021)
  • Table 26. Asia Pacific Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 27. Asia Pacific Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 28. Asia Pacific Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 29. China Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 30. China Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 31. China Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 32. Japan Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 33. Japan Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 34. Japan Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 35. India Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 36. India Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 37. India Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 38. South Korea Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 39. South Korea Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 40. South Korea Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 41. Taiwan Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 42. Taiwan Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 43. Taiwan Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 44. Australia Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 45. Australia Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 46. Australia Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 50. Europe Bacterial Vaginosis Drug, by Country USD Million (2016-2021)
  • Table 51. Europe Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 52. Europe Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 53. Europe Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 54. Germany Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 55. Germany Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 56. Germany Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 57. France Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 58. France Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 59. France Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 60. Italy Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 61. Italy Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 62. Italy Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 63. United Kingdom Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 64. United Kingdom Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 65. United Kingdom Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 66. Netherlands Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 67. Netherlands Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 68. Netherlands Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 69. Rest of Europe Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 70. Rest of Europe Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 71. Rest of Europe Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 72. MEA Bacterial Vaginosis Drug, by Country USD Million (2016-2021)
  • Table 73. MEA Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 74. MEA Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 75. MEA Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 76. Middle East Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 77. Middle East Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 78. Middle East Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 79. Africa Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 80. Africa Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 81. Africa Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 82. North America Bacterial Vaginosis Drug, by Country USD Million (2016-2021)
  • Table 83. North America Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 84. North America Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 85. North America Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 86. United States Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 87. United States Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 88. United States Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 89. Canada Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 90. Canada Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 91. Canada Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 92. Mexico Bacterial Vaginosis Drug, by Type USD Million (2016-2021)
  • Table 93. Mexico Bacterial Vaginosis Drug, by Application USD Million (2016-2021)
  • Table 94. Mexico Bacterial Vaginosis Drug, by End Users USD Million (2016-2021)
  • Table 95. Bacterial Vaginosis Drug: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Bacterial Vaginosis Drug: by Type(USD Million)
  • Table 107. Bacterial Vaginosis Drug Rx , by Region USD Million (2022-2027)
  • Table 108. Bacterial Vaginosis Drug OTC , by Region USD Million (2022-2027)
  • Table 109. Bacterial Vaginosis Drug: by Application(USD Million)
  • Table 110. Bacterial Vaginosis Drug Hospital , by Region USD Million (2022-2027)
  • Table 111. Bacterial Vaginosis Drug Pharmacy , by Region USD Million (2022-2027)
  • Table 112. Bacterial Vaginosis Drug Others , by Region USD Million (2022-2027)
  • Table 113. Bacterial Vaginosis Drug: by End Users(USD Million)
  • Table 114. Bacterial Vaginosis Drug Hospital , by Region USD Million (2022-2027)
  • Table 115. Bacterial Vaginosis Drug Pharmacy , by Region USD Million (2022-2027)
  • Table 116. Bacterial Vaginosis Drug Other , by Region USD Million (2022-2027)
  • Table 117. South America Bacterial Vaginosis Drug, by Country USD Million (2022-2027)
  • Table 118. South America Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 119. South America Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 120. South America Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 121. Brazil Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 122. Brazil Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 123. Brazil Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 124. Argentina Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 125. Argentina Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 126. Argentina Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 127. Rest of South America Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 128. Rest of South America Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 129. Rest of South America Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 130. Asia Pacific Bacterial Vaginosis Drug, by Country USD Million (2022-2027)
  • Table 131. Asia Pacific Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 132. Asia Pacific Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 133. Asia Pacific Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 134. China Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 135. China Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 136. China Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 137. Japan Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 138. Japan Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 139. Japan Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 140. India Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 141. India Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 142. India Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 143. South Korea Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 144. South Korea Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 145. South Korea Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 146. Taiwan Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 147. Taiwan Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 148. Taiwan Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 149. Australia Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 150. Australia Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 151. Australia Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 152. Rest of Asia-Pacific Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 153. Rest of Asia-Pacific Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 155. Europe Bacterial Vaginosis Drug, by Country USD Million (2022-2027)
  • Table 156. Europe Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 157. Europe Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 158. Europe Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 159. Germany Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 160. Germany Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 161. Germany Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 162. France Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 163. France Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 164. France Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 165. Italy Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 166. Italy Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 167. Italy Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 168. United Kingdom Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 169. United Kingdom Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 170. United Kingdom Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 171. Netherlands Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 172. Netherlands Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 173. Netherlands Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 174. Rest of Europe Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 175. Rest of Europe Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 176. Rest of Europe Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 177. MEA Bacterial Vaginosis Drug, by Country USD Million (2022-2027)
  • Table 178. MEA Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 179. MEA Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 180. MEA Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 181. Middle East Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 182. Middle East Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 183. Middle East Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 184. Africa Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 185. Africa Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 186. Africa Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 187. North America Bacterial Vaginosis Drug, by Country USD Million (2022-2027)
  • Table 188. North America Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 189. North America Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 190. North America Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 191. United States Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 192. United States Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 193. United States Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 194. Canada Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 195. Canada Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 196. Canada Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 197. Mexico Bacterial Vaginosis Drug, by Type USD Million (2022-2027)
  • Table 198. Mexico Bacterial Vaginosis Drug, by Application USD Million (2022-2027)
  • Table 199. Mexico Bacterial Vaginosis Drug, by End Users USD Million (2022-2027)
  • Table 200. Bacterial Vaginosis Drug: by Type(USD/Units)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bacterial Vaginosis Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Bacterial Vaginosis Drug: by Application USD Million (2016-2021)
  • Figure 6. Global Bacterial Vaginosis Drug: by End Users USD Million (2016-2021)
  • Figure 7. South America Bacterial Vaginosis Drug Share (%), by Country
  • Figure 8. Asia Pacific Bacterial Vaginosis Drug Share (%), by Country
  • Figure 9. Europe Bacterial Vaginosis Drug Share (%), by Country
  • Figure 10. MEA Bacterial Vaginosis Drug Share (%), by Country
  • Figure 11. North America Bacterial Vaginosis Drug Share (%), by Country
  • Figure 12. Global Bacterial Vaginosis Drug: by Type USD/Units (2016-2021)
  • Figure 13. Global Bacterial Vaginosis Drug share by Players 2021 (%)
  • Figure 14. Global Bacterial Vaginosis Drug share by Players (Top 3) 2021(%)
  • Figure 15. Global Bacterial Vaginosis Drug share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2021
  • Figure 19. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer (Germany) Revenue: by Geography 2021
  • Figure 21. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi (France) Revenue: by Geography 2021
  • Figure 23. Piramal (India) Revenue, Net Income and Gross profit
  • Figure 24. Piramal (India) Revenue: by Geography 2021
  • Figure 25. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott (United States) Revenue: by Geography 2021
  • Figure 27. Galderma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Galderma (Switzerland) Revenue: by Geography 2021
  • Figure 29. Alkem (India) Revenue, Net Income and Gross profit
  • Figure 30. Alkem (India) Revenue: by Geography 2021
  • Figure 31. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva (Israel) Revenue: by Geography 2021
  • Figure 33. Perrigo (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Perrigo (Ireland) Revenue: by Geography 2021
  • Figure 35. Starpharma (Australia) Revenue, Net Income and Gross profit
  • Figure 36. Starpharma (Australia) Revenue: by Geography 2021
  • Figure 37. Global Bacterial Vaginosis Drug: by Type USD Million (2022-2027)
  • Figure 38. Global Bacterial Vaginosis Drug: by Application USD Million (2022-2027)
  • Figure 39. Global Bacterial Vaginosis Drug: by End Users USD Million (2022-2027)
  • Figure 40. South America Bacterial Vaginosis Drug Share (%), by Country
  • Figure 41. Asia Pacific Bacterial Vaginosis Drug Share (%), by Country
  • Figure 42. Europe Bacterial Vaginosis Drug Share (%), by Country
  • Figure 43. MEA Bacterial Vaginosis Drug Share (%), by Country
  • Figure 44. North America Bacterial Vaginosis Drug Share (%), by Country
  • Figure 45. Global Bacterial Vaginosis Drug: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Bayer (Germany)
  • Sanofi (France)
  • Piramal (India)
  • Abbott (United States)
  • Galderma (Switzerland)
  • Alkem (India)
  • Teva (Israel)
  • Perrigo (Ireland)
  • Starpharma (Australia)
Additional players considered in the study are as follows:
Xiuzheng (China)
Select User Access Type

Key Highlights of Report


Aug 2022 159 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bacterial Vaginosis Drug Quantitative research analysis
Global Bacterial Vaginosis Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Bayer (Germany), Sanofi (France), Piramal (India), Abbott (United States), Galderma (Switzerland), Alkem (India), Teva (Israel), Perrigo (Ireland) and Starpharma (Australia) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising awareness about the women’s health" is seen as one of major influencing trends for Bacterial Vaginosis Drug Market during projected period 2021-2027.
The Bacterial Vaginosis Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Bacterial Vaginosis Drug Report?

Have a Query? Click Here

Other Related Reports

Microcapsules Comprehensive Study by Type (Ethyl cellulose, Polyvinyl alcohol, Gelatin, Sodium Alginate), Application (Pharmaceutical & healthcare products, Food & beverages, Household & personal car...
$ 3750
Myoglobin Comprehensive Study by Type (Human Myoglobin, Animal Myoglobin), Application (Hospital, Research Institute, Others), Form (Deoxymyoglobin, Oxymyoglobin) Players and Region - Global Market O...
$ 3500
Nutraceuticals Comprehensive Study by Type (Dietary Supplements, Functional Food, Functional Beverages), Application (Campus Safety, Domestic Violence, Cyber Intrusion, Cyber Intrusion, Physical Heal...
$ 3800
Vascular Patches Comprehensive Study by Application (Carotid Endarterectomy, Vascular Bypass Surgery, Open Repair of Abdominal Aortic Aneurysms, Others), Material (Biologic Vascular Patches, Syntheti...
$ 3450
Tasigna Comprehensive Study by Type (50mg, 100mg, 150mg, 200mg, Others), Patients Type (Adult, Pediatric), Distribution Channel (Online, Offline), End User (Hospital, Drugs Store, Other) Players and ...
$ 3500
Hemostatic Sponge Comprehensive Study by Application (Surgical Wound Care, General Wound Care), End-user (Hospitals, Clinics, Others), Component (Gelatin, Cellulose, Chitosan) Players and Region - Gl...
$ 3500